A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00532077
First received: September 17, 2007
Last updated: October 13, 2010
Last verified: October 2010
  Purpose

SB-751689 may alter calcium and phosphate handling at the kidney level. This study will examine what happens to calcium and phosphate, and other electrolytes, at the kidney after treatment with SB-751689 for 1 month. Another group of subjects will get another drug called Forteo for 1 month to compare the response of the kidney for calcium and phosphate.


Condition Intervention Phase
Osteoporosis
Drug: rhPTH(1-34)
Drug: SB-751689 100 mg
Drug: SB-751689 400 mg
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Exploratory, Open Label, Multicenter Parallel Group Study to Evaluate the Effects of Single and Repeat Dosing of SB-751689 (400 mg or 100 mg) or rhPTH(1-34) on the Fractional Renal Excretion of Calcium and Phosphate in Healthy Postmenopausal Females.

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • renal fractional clearance of calcium and phosphate [ Time Frame: over 1 month ]

Secondary Outcome Measures:
  • renal fraction clearance of electrolytes, cAMP, safety measures, and serum biomarkers [ Time Frame: over 1 month ]
  • urinary excretion of sodium, magnesium, potassium, bicarbonate, and chloride
  • Albumin-adjusted serum calcium levels
  • Vitamin D and P1NP levels
  • Plasma levels of SB-751689 and rhPTH(1-34)
  • Plasma PTH
  • Adverse event reports, 12-lead ECGs, vital signs, nursing/physician observation and laboratory tests.

Enrollment: 40
Study Start Date: August 2007
Study Completion Date: January 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: rhPTH(1-34) Drug: SB-751689 100 mg Drug: SB-751689 400 mg
    Other Names:
    • rhPTH(1-34)
    • SB-751689 100 mg
    • SB-751689 400 mg
  Eligibility

Ages Eligible for Study:   40 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy postmenopausal women 40 to 65 years of age, inclusive, meeting at least one of the following: Postmenopausal defined by the STRAW criteria of 12 months of spontaneous amenorrhea with serum FSH levels = 40 mIU/mL; History of bilateral oophorectomy (with or without hysterectomy) and at least 6 weeks post-surgical with serum FSH levels = 40 mIU/mL
  • Body weight > 50 kg and BMI within the range 19 - 32 kg/m2
  • Capable of giving written informed consent

Exclusion Criteria:

  • Any clinically relevant biological or physical abnormality found or reported at screening which, in the opinion of the investigator, is clinically significant and would preclude safe participation in this study. These abnormalities may be identified on the screening history and physical or laboratory examination and 12-lead electrocardiogram (ECG).
  • A subject may not participate in the study if any of the following laboratory results are above the upper limit of the normal range at screening: liver function tests (ALT, AST, GGT, alkaline phosphatase, total bilirubin), plasma amylase, glucose, alkaline phosphatase, or CPK.
  • A subject may not participate in the study if any of the following laboratory results are outside the normal range at screening: serum levels of albumin-adjusted calcium, total calcium, PTH, and urinary calcium.
  • A subject with vitamin D deficiency as defined by serum 25-hydroxy vitamin D < 20 ng/mL (equivalent to 50 nmol/L) at screening may not participate in the study. A QTc interval > 450 msec at screening.
  • Positive urine drug screen.
  • Positive for HIV, hepatitis B virus or hepatitis C virus assays.
  • Urinary cotinine levels indicative of smoking.
  • History of smoking or use of nicotine containing products within one year of screening.
  • History of regular alcohol consumption
  • History of drug abuse within 6 months of the study.
  • Participation in a study with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • Use of prescription or non-prescription drugs, calcium containing antacids, aspirin or nonsteroidal anti-inflammatory drugs, vitamins, herbal and dietary supplements, excluding study related vitamin D and calcium supplements, within 14 days prior to the first dose of study medication.
  • Donation of blood in excess of 500 mL within 56 days prior to dosing.
  • Evidence of hepatic or biliary disease (including cholecystectomy and Gilbert's Syndrome).
  • Significant renal disease as define by:
  • Serum creatinine clearance <60ml/min (estimated from serum creatinine (SCr) and demographic data using the MDRD calculation):
  • A validated web-based calculator is found at: http://nephron.com/cgi-bin/MDRDSIdefault.cgi
  • GFR Calculator
  • To calculate estimated GFR (mL/min/1.73m2) manually:
  • = 186 x (SCr in mg/dL)-1.154 x (age)-0.203 x (0.742 if female) x (1.210 if African-American)
  • = exp(5.228-1.154 x ln (SCr)-0.203x ln(age)-(0.299 if female) + (0.192 if African American))
  • Urine protein/creatinine (mg/mg) ratio >2.5; or urine albumin concentration > 300 ug/mg.
  • Known loss of kidney, either surgically or by injury or disease
  • History of significant gastrointestinal
  • History of a gastrointestinal surgical procedure that might affect the absorption of SB-751689
  • History of sensitivity to any of the study medications or components thereof.
  • History of clinically significant cardiovascular disease.
  • History of pancreatitis or kidney stones. Medical conditions which might alter bone metabolism
  • Subjects at increased risk of osteosarcoma such as those with Paget's disease of the bone or any prior external beam or implant radiation therapy involving the skeleton.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00532077

Locations
United States, California
GSK Investigational Site
San Diego, California, United States, 92123
United States, Florida
GSK Investigational Site
Daytona Beach, Florida, United States, 32117
GSK Investigational Site
Port Orange, Florida, United States, 32127
United States, Hawaii
GSK Investigational Site
Honolulu, Hawaii, United States, 96813
United States, Texas
GSK Investigational Site
Austin, Texas, United States, 78752
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials, MD GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Study Director, GSK
ClinicalTrials.gov Identifier: NCT00532077     History of Changes
Other Study ID Numbers: CR9108122
Study First Received: September 17, 2007
Last Updated: October 13, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
renal,
pharmacology,
Osteoporosis

Additional relevant MeSH terms:
Osteoporosis
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases

ClinicalTrials.gov processed this record on August 27, 2014